{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:51:34Z","timestamp":1790297494650,"version":"4.1.0"},"reference-count":146,"publisher":"Impact Journals, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2018,12,18]]},"DOI":"10.18632\/aging.101707","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T21:42:35Z","timestamp":1545169355000},"page":"4248-4268","source":"Crossref","is-referenced-by-count":15,"title":["How I treat elderly patients with plasma cell dyscrasias"],"prefix":"10.18632","volume":"10","author":[{"given":"Maria","family":"Gavriatopoulou","sequence":"first","affiliation":[{"name":"Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, Athens 11528, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, Athens 11528, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, Athens 11528, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, Athens 11528, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, Athens 11528, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Alexandra Hospital, Oncology Department, Department of Therapeutics, National and Kapodistrian University of Athens, Athens 11528, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"1","unstructured":"United Nations. 2018. http:\/\/www.un.org\/en\/sections\/issues-depth\/ageing\/."},{"key":"2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","article-title":"Frailty and the management of hematologic malignancies.","volume":"13","author":"Klepin","year":"2018","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review.","volume":"3","author":"Stauder","year":"2014","journal-title":"Leuk Res"},{"key":"4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/gerona\/59.3.M255","article-title":"Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care.","volume":"5","author":"Anderson","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jgo.2018.03.014","article-title":"The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients - A systematic review.","volume":"9","author":"van Huis","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer.","volume":"2","author":"Hurria","year":"2007","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.ejca.2010.01.006","article-title":"Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?","volume":"4","author":"Wildiers","year":"2010","journal-title":"Eur J Cancer"},{"key":"8","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).","volume":"11","author":"Davies","year":"2011","journal-title":"Blood"},{"key":"9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity.","volume":"12","author":"Anderson","year":"2015","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1517\/14656566.2013.805746","article-title":"New developments in the management and treatment of newly diagnosed and relapsed\/refractory multiple myeloma patients.","volume":"1","author":"Lokhorst","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"11","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.","volume":"2","author":"Russell","year":"2014","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.12465","article-title":"Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.","volume":"16","author":"Sacchi","year":"2013","journal-title":"Br J Haematol"},{"key":"13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.","volume":"1","author":"Gonz\u00e1lez","year":"2010","journal-title":"Lancet Oncol"},{"key":"14","first-page":"242","article-title":"Are we making progress? Survival in plasma cell malignancies in the era of novel treatments. A population based study of 17790 patients in the Netherlands [abstract].","volume":"9","author":"Blommenstein","year":"2012","journal-title":"Haematologica"},{"key":"15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0609.2005.00532.x","article-title":"Multiple myeloma in elderly patients: prognostic factors and outcome.","volume":"7","author":"Dimopoulos","year":"2005","journal-title":"Eur J Haematol"},{"key":"16","first-page":"51","article-title":"Age is not a prognostic variable with autotransplants for multiple myeloma.","volume":"9","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma.","volume":"2","author":"Avet-Loiseau","year":"2014","journal-title":"Leukemia"},{"key":"18","first-page":"in press","article-title":"Vulnerability variables among Octagenarians Myeloma patients: A Single -Center Analysis in 110 Patients.","author":"Ziogas","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"19","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"11","author":"Pulte","year":"2008","journal-title":"Blood"},{"key":"20","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3324\/haematol.2017.173617","article-title":"Treat or palliate: outcomes of very elderly myeloma patients.","volume":"10","author":"Ramasamy","year":"2018","journal-title":"Haematologica"},{"key":"21","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).","volume":"3","author":"Bringhen","year":"2018","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials.","volume":"34","author":"Albain","year":"1999","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1200\/JCO.2004.06.050","article-title":"Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer.","volume":"2","author":"Cohen","year":"2004","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1056\/NEJMsa012528","article-title":"Understanding the treatment preferences of seriously ill patients.","volume":"34","author":"Allore","year":"2002","journal-title":"N Engl J Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"1","author":"Dispenzieri","year":"2014","journal-title":"Lancet Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgo.2016.04.001","article-title":"Management of multiple myeloma in older adults: gaining ground with geriatric assessment.","volume":"8","author":"Campagnaro","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"2","author":"Morgan","year":"2005","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.clml.2013.07.003","article-title":"Multiple myeloma international staging system: \u201cstaging\u201d or simply \u201caging\u201d system?","volume":"1","author":"Beauchet","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"29","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.","volume":"3","author":"Attal","year":"2015","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.","volume":"12","author":"Terpos","year":"2015","journal-title":"Blood"},{"key":"31","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.","volume":"9","author":"Lin","year":"2016","journal-title":"Am J Hematol"},{"key":"32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.clml.2016.04.010","article-title":"Prognostic Effect of Low Subcutaneous Adipose Tissue on Survival Outcome in Patients With Multiple Myeloma.","volume":"1","author":"Ohta","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2012.067058","article-title":"Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.","volume":"9","author":"P\u00e9gouri\u00e9","year":"2013","journal-title":"Haematologica"},{"key":"34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.","volume":"11","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"35","author":"Schots","year":"2008","journal-title":"N Engl J Med"},{"key":"36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.","volume":"3","author":"Delforge","year":"2013","journal-title":"J Clin Oncol"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos MA, Jahek R, et al. Phase 3 study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM). International Myeloma Workshop2017.","DOI":"10.1016\/j.clml.2017.03.045"},{"key":"38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.","volume":"38","author":"Dispenzieri","year":"2017","journal-title":"Lancet"},{"key":"39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.","volume":"37","author":"Grosicki","year":"2018","journal-title":"N Engl J Med"},{"key":"40","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"36","author":"Cavo","year":"2012","journal-title":"N Engl J Med"},{"key":"41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.","volume":"13","author":"Delforge","year":"2018","journal-title":"Blood"},{"key":"42","unstructured":"Jackson G, Davies FE, Pawlyn C, Caims D, Striha A, Hockaday A, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk. Results of the myeloma XI Trial. ASH 59th Annual Meeting2017."},{"key":"43","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.","volume":"12","author":"Bernardini","year":"2016","journal-title":"Blood"},{"key":"44","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.","volume":"9","author":"Liberati","year":"2013","journal-title":"Haematologica"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.353","article-title":"Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.","author":"San-Miguel","year":"2017","journal-title":"Leukemia"},{"key":"46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/pds.3927","article-title":"Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.","volume":"2","author":"Cox","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.lrr.2015.09.002","article-title":"Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.","volume":"4","author":"Pe\u00f1alver","year":"2015","journal-title":"Leuk Res Rep"},{"key":"48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.","volume":"1","author":"Suvorov","year":"2016","journal-title":"Lancet Oncol"},{"key":"49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"37","author":"Suvorov","year":"2015","journal-title":"N Engl J Med"},{"key":"50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.","volume":"17","author":"Niesvizky","year":"2017","journal-title":"Br J Haematol"},{"key":"51","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.","volume":"37","author":"Ben Yehuda","year":"2016","journal-title":"N Engl J Med"},{"key":"52","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.","volume":"37","author":"Schecter","year":"2016","journal-title":"N Engl J Med"},{"key":"53","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.","volume":"1","author":"Cavo","year":"2013","journal-title":"Lancet Oncol"},{"key":"54","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.","volume":"37","author":"Beksac","year":"2015","journal-title":"N Engl J Med"},{"key":"55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.04.004","article-title":"Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation.","volume":"6","author":"Straka","year":"2016","journal-title":"Eur J Cancer"},{"key":"56","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.","volume":"10","author":"Scheid","year":"2018","journal-title":"Haematologica"},{"key":"57","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3324\/haematol.2016.151860","article-title":"Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.","volume":"10","author":"Pfreundschuh","year":"2016","journal-title":"Haematologica"},{"key":"58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","article-title":"Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.","volume":"1","author":"Engelhardt","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"59","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.","volume":"10","author":"W\u00e4sch","year":"2017","journal-title":"Haematologica"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Straka C, Schafer-Eckart K, Bassermann F, HertesteinB, Engelhardt M, Salwender H, et al. Prospective randomized trial of Len.Dex induction followed by tandem MEL140 with autologous blood stem cell transplantation and len maintenance versus continued therapy with Len\/Dex in myeloma patients age 60-75 years: protocol defined safety analysis [abstract]. Blood. 2012; 120:2012.","DOI":"10.1182\/blood.V120.21.2012.2012"},{"key":"61","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications.","volume":"10","author":"Larocca","year":"2015","journal-title":"Haematologica"},{"key":"62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.blre.2011.03.005","article-title":"Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?","volume":"2","author":"San Miguel","year":"2011","journal-title":"Blood Rev"},{"key":"63","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"35","author":"Blad\u00e9","year":"2005","journal-title":"N Engl J Med"},{"key":"64","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"35","author":"Olesnyckyj","year":"2007","journal-title":"N Engl J Med"},{"key":"65","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"35","author":"Patin","year":"2007","journal-title":"N Engl J Med"},{"key":"66","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00520-013-1766-y","article-title":"Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study.","volume":"2","author":"Mohile","year":"2013","journal-title":"Support Care Cancer"},{"key":"67","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma.","volume":"2","author":"Avet-Loiseau","year":"2012","journal-title":"Leukemia"},{"key":"68","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.","volume":"1","author":"Sonneveld","year":"2010","journal-title":"Lancet Oncol"},{"key":"69","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1055\/s-0034-1370793","article-title":"Venous thromboembolism in multiple myeloma.","volume":"4","author":"Rossi","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"70","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.","volume":"2","author":"Knop","year":"2008","journal-title":"Leukemia"},{"key":"71","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/leu.2011.3","article-title":"Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.","volume":"2","author":"Morgan","year":"2011","journal-title":"Leukemia"},{"key":"72","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.","volume":"2","author":"Hansson","year":"2014","journal-title":"Leukemia"},{"key":"73","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/jjco\/hyr063","article-title":"Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.","volume":"4","author":"Kitamura","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"74","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","article-title":"Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.","volume":"9","author":"Hajek","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"75","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.seminhematol.2009.03.006","article-title":"Infections in patients with multiple myeloma.","volume":"4","author":"Anaissie","year":"2009","journal-title":"Semin Hematol"},{"key":"76","unstructured":"Bowcock SP, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in newly diagnosed myeloma reduces febrile episodes and death without increasing healthcare associated infections: results from the TEAMM trial. EHA 2018."},{"key":"77","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.6004\/jnccn.2015.0137","article-title":"Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts.","volume":"1","author":"Dale","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.","volume":"1","author":"Henk","year":"2013","journal-title":"Oncologist"},{"key":"79","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00520-014-2122-6","article-title":"Quantifying the burden of informal caregiving for patients with cancer in Europe.","volume":"2","author":"DaCosta Dibonaventura","year":"2014","journal-title":"Support Care Cancer"},{"key":"80","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia.","volume":"12","author":"Treon","year":"2015","journal-title":"Blood"},{"key":"81","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes.","author":"Flowers","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"82","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.","volume":"10","author":"Vervessou","year":"2015","journal-title":"Haematologica"},{"key":"83","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/leu.2013.36","article-title":"How to manage Waldenstrom\u2019s macroglobulinemia.","volume":"2","author":"Leblond","year":"2013","journal-title":"Leukemia"},{"key":"84","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.","volume":"2","author":"Dreyling","year":"2018","journal-title":"Ann Oncol"},{"key":"85","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia.","volume":"11","author":"Merlini","year":"2009","journal-title":"Blood"},{"key":"86","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia.","volume":"3","author":"Leblond","year":"2003","journal-title":"Semin Oncol"},{"key":"87","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.critrevonc.2016.06.004","article-title":"Response rate to the treatment of Waldenstr\u00f6m macroglobulinemia: A meta-analysis of the results of clinical trials.","volume":"10","author":"Lucia","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"88","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","article-title":"Treatment recommendations for patients with Waldenstr\u00f6m macroglobulinemia (WM) and related disorders: IWWM-7 consensus.","volume":"12","author":"Morel","year":"2014","journal-title":"Blood"},{"key":"89","doi-asserted-by":"publisher","first-page":"vi155","DOI":"10.1093\/annonc\/mdt298","article-title":"Waldenstrom\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"2","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"90","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study.","volume":"12","author":"Vervessou","year":"2015","journal-title":"Blood"},{"key":"91","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.","volume":"38","author":"D\u00fcrk","year":"2013","journal-title":"Lancet"},{"key":"92","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.","volume":"12","author":"Dimopoulos","year":"2017","journal-title":"Blood"},{"key":"93","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Macroglobulinemia.","volume":"8","author":"Anderson","year":"2010","journal-title":"Am J Hematol"},{"key":"94","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.","volume":"2","author":"Boral","year":"2009","journal-title":"J Clin Oncol"},{"key":"95","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy466","article-title":"Waldenstrom\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","author":"Buske","year":"2018","journal-title":"Ann Oncol"},{"key":"96","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia.","volume":"12","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"97","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia.","volume":"12","author":"Morel","year":"2016","journal-title":"Blood"},{"key":"98","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and Management of Waldenstr\u00f6m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.","volume":"3","author":"Lacy","year":"2017","journal-title":"JAMA Oncol"},{"key":"99","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia.","volume":"37","author":"Zehnder","year":"2015","journal-title":"N Engl J Med"},{"key":"100","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.","volume":"1","author":"Cornell","year":"2017","journal-title":"Lancet Oncol"},{"key":"101","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia.","volume":"37","author":"Shustik","year":"2018","journal-title":"N Engl J Med"},{"key":"102","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance Rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.","volume":"15","author":"Turnbull","year":"2011","journal-title":"Br J Haematol"},{"key":"103","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","article-title":"European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.","volume":"3","author":"Dimopoulos","year":"2018","journal-title":"Leukemia"},{"key":"104","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.1993.11.7.1311","article-title":"Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.","volume":"1","author":"Alexanian","year":"1993","journal-title":"J Clin Oncol"},{"key":"105","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","article-title":"Update on treatment recommendations from the Fourth International Workshop on Waldenstrom\u2019s Macroglobulinemia.","volume":"2","author":"Ghobrial","year":"2009","journal-title":"J Clin Oncol"},{"key":"106","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.","volume":"3","author":"Dartigeas","year":"2013","journal-title":"J Clin Oncol"},{"key":"107","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr\u00f6m macroglobulinemia.","volume":"9","author":"Treon","year":"2016","journal-title":"Am J Hematol"},{"key":"108","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstr\u00f6m macroglobulinemia treated with nucleoside analogs.","volume":"2","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"key":"109","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstr\u00f6m macroglobulinemia: an analysis of the SEER database.","volume":"12","author":"Treon","year":"2015","journal-title":"Cancer"},{"key":"110","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones.","volume":"10","author":"Stone","year":"2006","journal-title":"Blood"},{"key":"111","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/978-94-007-5416-4_22","article-title":"The challenge of systemic immunoglobulin light-chain amyloidosis (Al).","volume":"6","author":"Comenzo","year":"2012","journal-title":"Subcell Biochem"},{"key":"112","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"35","author":"Melton","year":"2006","journal-title":"N Engl J Med"},{"key":"113","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/gerona\/59.4.M361","article-title":"Amyloidosis: a universal disease of aging?","volume":"5","author":"Blumenthal","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"114","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejim.2018.05.004","article-title":"Management of the elderly patient with AL amyloidosis.","volume":"5","author":"Merlini","year":"2018","journal-title":"Eur J Intern Med"},{"key":"115","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"12","author":"Merlini","year":"2016","journal-title":"Blood"},{"key":"116","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.","volume":"3","author":"Russell","year":"2012","journal-title":"J Clin Oncol"},{"key":"117","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.","volume":"8","author":"Merlini","year":"2012","journal-title":"Am J Hematol"},{"key":"118","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3324\/haematol.2015.128025","article-title":"Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.","volume":"10","author":"Wechalekar","year":"2015","journal-title":"Haematologica"},{"key":"119","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.","volume":"12","author":"Sch\u00f6nland","year":"2014","journal-title":"Blood"},{"key":"120","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.mayocp.2017.09.016","article-title":"Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.","volume":"9","author":"Falk","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"121","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin\u00a0Cardiac Amyloidosis and\u00a0Risk Stratification Using a Novel\u00a0Staging System.","volume":"6","author":"Dispenzieri","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"122","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.","volume":"34","author":"Hawkins","year":"2002","journal-title":"N Engl J Med"},{"key":"123","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MD.0b13e31816c43b6","article-title":"The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.","volume":"8","author":"Gisserot","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"124","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clml.2013.02.001","article-title":"Diagnostic challenges of amyloidosis in Waldenstr\u00f6m macroglobulinemia.","volume":"1","author":"Merlini","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"125","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.","volume":"3","author":"Merlini","year":"2012","journal-title":"J Clin Oncol"},{"key":"126","doi-asserted-by":"crossref","unstructured":"Kanapuru BS, Myers A, Beaver JA, Kwitkowski VE, Farrell AT, et al. Enrollment of older adults in clinical trials and evaluating paeints with hematologic malignancies - the Food and Drug Adminstration (FDA) experience [abstract]. Blood. 2017; 130:861.","DOI":"10.1182\/blood.V130.Suppl_1.861.861"},{"key":"127","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1182\/blood-2006-06-029728","article-title":"Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.","volume":"10","author":"Sanchorawala","year":"2006","journal-title":"Blood"},{"key":"128","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3324\/haematol.12136","article-title":"Bortezomib in the treatment of AL amyloidosis: targeted therapy?","volume":"9","author":"Merlini","year":"2007","journal-title":"Haematologica"},{"key":"129","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.","volume":"9","author":"Merlini","year":"2014","journal-title":"Haematologica"},{"key":"130","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.","volume":"11","author":"Wechalekar","year":"2012","journal-title":"Blood"},{"key":"131","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.","volume":"11","author":"Fonseca","year":"2012","journal-title":"Blood"},{"key":"132","doi-asserted-by":"crossref","unstructured":"Merlini G, Sachorawala V, Jeffrey ZA., Kukreti V, Schoenland SO, Jaccard A, et al. Long-Term Outcome of a Phase 1 Study of the Investigational Oral Protea-some Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL) [abstract]. Blood. 2014; 124:3450.","DOI":"10.1182\/blood.V124.21.3450.3450"},{"key":"133","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.","volume":"9","author":"Merlini","year":"2012","journal-title":"Ann Hematol"},{"key":"134","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.","volume":"11","author":"Fonseca","year":"2012","journal-title":"Blood"},{"key":"135","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.","volume":"11","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"136","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.","volume":"13","author":"Liedtke","year":"2017","journal-title":"Blood"},{"key":"137","doi-asserted-by":"crossref","unstructured":"Edwards CV, Langer AL, Mapara MY, Radhakrishman J. Maurer MS et al. Final analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis. ASH 59th annual meeting and exposition; Atlanta: Blood 2017.","DOI":"10.1182\/blood.V128.22.643.643"},{"key":"138","doi-asserted-by":"publisher","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.","volume":"1","author":"Pepys","year":"2018","journal-title":"Sci Transl Med"},{"key":"139","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-Human Phase I\/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.","volume":"3","author":"Liedtke","year":"2016","journal-title":"J Clin Oncol"},{"key":"140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies.","volume":"201","author":"Merlini","year":"2017","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"141","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.","volume":"13","author":"Merlini","year":"2018","journal-title":"Blood"},{"key":"142","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1200\/JCO.2016.68.6113","article-title":"Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach.","volume":"3","author":"Palumbo","year":"2016","journal-title":"J Clin Oncol"},{"key":"143","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy.","volume":"6","author":"Cohen","year":"1981","journal-title":"Circulation"},{"key":"144","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents.","volume":"5","author":"Kyle","year":"1985","journal-title":"Am J Cardiol"},{"key":"145","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.","volume":"5","author":"Bauer","year":"2008","journal-title":"Heart Rhythm"},{"key":"146","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1586\/14737140.2014.856269","article-title":"Optimal management of elderly patients with myeloma.","volume":"1","author":"Palumbo","year":"2014","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.101707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T18:54:34Z","timestamp":1662663274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.101707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":146,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,31]]}},"alternative-id":["101707","30568029"],"URL":"https:\/\/doi.org\/10.18632\/aging.101707","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]}}}